Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2015 Nov 30;15(1):72–83. doi: 10.1158/1535-7163.MCT-15-0600

Figure 5. ML264 inhibits the growth of DLD-1-derived tumor xenografts in nude mice model.

Figure 5

DLD-1 cells were subcutaneously injected into nude mice for the development of xenograft tumors. Mice were treated with vehicle only or with ML264 as follows: daily with 10mg/kg (A, D), twice per day with 10mg/kg (B, E) or twice per day with 25mg/kg (C, F) as detailed in Materials and Methods. Black lines label vehicle-treated mice, and red lines label ML264-treated mice. Black arrows point to the start of injections of vehicle or ML264. Tumor volume is depicted in A–C and mice weight in D–F. The asterisks (***) and (****) indicate a significant difference (p < 0.001) and (p < 0.0001), respectively, between the ML264-treated and vehicle-treated groups. (G) Photographic images of the tumor collected at the end of 10 days treatment as shown in (B) and (C).